DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Da-Eun | ko |
dc.contributor.author | Ryou, Jeong-Hyun | ko |
dc.contributor.author | Oh, Jong Rok | ko |
dc.contributor.author | Han, Jung Woo | ko |
dc.contributor.author | Park, Tae Kwann | ko |
dc.contributor.author | Kim, Hak-Sung | ko |
dc.date.accessioned | 2016-06-30T00:34:36Z | - |
dc.date.available | 2016-06-30T00:34:36Z | - |
dc.date.created | 2016-04-19 | - |
dc.date.created | 2016-04-19 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | PLOS ONE, v.11, no.3 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/10203/208660 | - |
dc.description.abstract | Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness among people over the age of 60. Vascular endothelial growth factor (VEGF) plays a major role in pathological angiogenesis in AMD. Herein, we present the development of an antihuman VEGF repebody, which is a small-sized protein binder consisting of leucine-rich repeat (LRR) modules. The anti-VEGF repebody selected through a phage-display was shown to have a high affinity and specificity for human VEGF. We demonstrate that this repebody effectively inhibits in vitro angiogenic cellular processes, such as proliferation and migration, by blocking the VEGF-mediated signaling pathway. The repebody was also shown to have a strong suppression effect on choroidal neovascularization (CNV) and vascular leakage in vivo. Our results indicate that the anti-VEGF repebody has a therapeutic potential for treating neovascular AMD as well as other VEGF-involved diseases including diabetic retinopathy and metastatic cancers | - |
dc.language | English | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | MACULAR DEGENERATION | - |
dc.subject | PROTEIN BINDER | - |
dc.subject | BASIC SCIENCE | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | RANIBIZUMAB | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | MECHANISMS | - |
dc.subject | ANTIBODIES | - |
dc.subject | PROGRESS | - |
dc.title | Anti-Human VEGF Repebody Effectively Suppresses Choroidal Neovascularization and Vascular Leakage | - |
dc.type | Article | - |
dc.identifier.wosid | 000372708900072 | - |
dc.identifier.scopusid | 2-s2.0-84979670558 | - |
dc.type.rims | ART | - |
dc.citation.volume | 11 | - |
dc.citation.issue | 3 | - |
dc.citation.publicationname | PLOS ONE | - |
dc.identifier.doi | 10.1371/journal.pone.0152522 | - |
dc.contributor.localauthor | Kim, Hak-Sung | - |
dc.contributor.nonIdAuthor | Oh, Jong Rok | - |
dc.contributor.nonIdAuthor | Han, Jung Woo | - |
dc.contributor.nonIdAuthor | Park, Tae Kwann | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | MACULAR DEGENERATION | - |
dc.subject.keywordPlus | PROTEIN BINDER | - |
dc.subject.keywordPlus | BASIC SCIENCE | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | RANIBIZUMAB | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | ANTIBODIES | - |
dc.subject.keywordPlus | PROGRESS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.